Certainly hope so. Some good signs recently.
1.
Mr Proulx said the company’s initial goal was 12 to 15 patients by the end of 2021.
“We are clearly not in a position to achieve that, but I think we will have made substantial
progress,” he says.
The key endpoints are safety and tolerability, which is not likely to pose too many
problems given iron oxide has been used as an imaging adjunct for three decades.
The active component - the antibody - is a form of the commonly used cancer drug
Herceptin, but about one per cent of the strength used in therapy.
Source : Biotech Daily December 17, 2021
2. 26th November 2021
Recent Video presentation confirming "Multiple" (here is favorite word again) patients have been enrolled and completed the course of study. Special mention to Siemens for their support. Plans to leave the enrollment open to inform further product development of Pivotal study in US.
3. Larger facility for bigger team and increased production and research capability (Getting ready for Pivotal study)
4. New Director of Operations recruited in November 2021.
5. New Chief Development Officer - September 2021
